Variety of eligible individuals: CDEC mentioned the uncertainty in the number of patients with moderately severe to severe hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some sufferers who will be labeled as acquiring delicate or moderate illness could have a extreme bleeding